Results of 5 phase 3 studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood, were presented at the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14), in Washington, D.C
Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
FDA has approved non-prescription esomeprazole 20mg (Nexium 24HR, Pfizer).
A partnership between Catamaran and Health New England achieved a 30% reduction in 30-day readmissions, presented at Session 216 at AMCP
FDA is slowly implementing draft guidelines for bringing biosimilars to market, while states are enacting laws requiring additional notification and record keeping for the products
More evidence-based treatment sequencing must be put into practice to reduce the number of medications patients use on a trial-and-error basis
In 2014 and beyond, pharmacy leaders should watch for more oral drugs and more expanded indications of specialty drugs.
Reducing readmissions has clinical and financial benefit, but key challenges must be addressed
In a study recently published in Nursing 2014, atrial fibrillation patients on warfarin therapy who self-tested their coagulation (via international normalized ratio [INR]) and were remanaged by their clinicians using a “Management by Exception” protocol had better warfarin control than traditional self-testers.1 The protocol, in which patients followed specific clinic-issued, written instructions for managing out-of-range INR self-test results within a predetermined safety range, also benefited clinics by reducing the need for telephone follow-up and related costs.
Poor adherence to prescription drug regimens has long been seen as a substantial roadblock to achieving better outcomes for patients. Data show that as many as half of all patients do not adhere faithfully to their prescriptions, and the result is more than $290 billion spent each year on avoidable medical treatment.
With total healthcare costs in the United States approaching $3 trillion, and costs for a wide range of drugs approaching nearly 15% of healthcare costs overall, or $450 billion, the industry is shifting toward a new emphasis focused on drug formularies.
FDA actions in brief, fast-track designation, orphan drug designation, first-time generic approvals
Prepare for a significant increase in self-pay liabilities from the “high-deductible“ patient population or risk a reduced level of reimbursement
Community Health Choice CEO Ken Janda foresees more private coverage for the state and the country under health reform 2.0
Payment changes will save an estimated $200 million annually.
Mammograms contribute 62% of the cost and the remaining 38% is attributed to follow-on diagnostics.
Coverage of circulating tumor cell (CTC) assays could be discontinued for beneficiaries in certain states.
Bronze plans have highest drug cost-sharing increase.
CMS is driving down rates for MA plans while taxes and dwindling bonus pay pile on the pain
Value-based designs aren’t just nice add-ons, but rather they represent new business propositions
Who knows how many late-comers will plea for special enrollment
One-fourth of Akron Ohio's SummaCare enrollees are among the coveted younger population
Break down silos to improve access and affordability
Medicare patients incur higher out-of-pocket costs when they are placed on observation status
Influenza vaccination reduced children’s risk of pediatric intensive care unit (PICU) admission for flu by three-fourths during 2010 to 2011 and 2011to 2012, according to a Centers for Disease Control and Prevention (CDC) study published online March 26 in the Journal of Infectious Diseases.
Idarucizumab (Fab, Boehringer Ingelheim), an investigational humanized antibody fragment being studied as a specific antidote for dabigatran (Pradaxa), reversed dabigatran anticoagulation, even in the presence of elevated dabigatran levels and life-threatening bleeding from severe trauma, in animals, according to a study presented at the American College of Cardiology 63rd Annual Scientific Session (ACC.14), Washington, D.C.
Data from a phase 3 study comparing the low-density lipoprotein-cholesterol (LDLc)–lowering efficacy and safety of alirocumab, an investigational PCSK9 inhibitor, versus ezetemibe in patients not receiving statin or other lipid-lowering therapies was presented at the ACC.14, the American College of Cardiology’s 63rd Annual Scientific Session & Expo in Washington, D.C.
FDA has approved Coagulation Factor IX (Recombinant), Fc Fusion Protein (Alprolix, Biogen Idec), for use in adults and children who have hemophilia B; it also granted the product orphan-drug designation. Alprolix is the first hemophilia B treatment designed for less frequent injections when used to prevent or reduce bleeding frequency.
Just like most of the Affordable Care Act implementation, the enrollment deadline is causing plenty of consumer confusion
Official HHS guidance for plans and consumers
